Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists

Geoffrey S Gottlieb; Cammie F Lesser; King K Holmes; Anna Wald

doi:10.1086/377235

Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists

Clin Infect Dis. 2003 Sep 15;37(6):838-40. doi: 10.1086/377235. Epub 2003 Aug 23.

Authors

Geoffrey S Gottlieb¹, Cammie F Lesser, King K Holmes, Anna Wald

Affiliation

¹ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98195, USA. gottlieb@u.washington.edu

PMID: 12955647
DOI: 10.1086/377235

Abstract

We report a case of disseminated sporotrichosis in a 49-year-old man who was treated with multiple immunosuppressants, including tumor necrosis factor (TNF)-alpha antagonists (etanercept and infliximab), for presumed inflammation arthritis. This case illustrates the potential for infectious complications related to the use of cytotoxic immunosuppressants and anticytokine agents, such as TNF-alpha antagonists.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Arthritis / complications
Arthritis / drug therapy
Etanercept
Humans
Immunoglobulin G / adverse effects*
Immunoglobulin G / therapeutic use
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Infliximab
Male
Middle Aged
Receptors, Tumor Necrosis Factor / therapeutic use
Sporotrichosis / etiology*
Sporotrichosis / transmission
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Immunoglobulin G
Immunosuppressive Agents
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Infliximab
Etanercept